Notizie AIOM – anno XV n. 648
FDA Grants Priority Review to Durvalumab for Locally Advanced Unresectable NSCLC
October 17, 2017 - The FDA has granted a priority review to a supplemental biologics license application (sBLA) for durvalumab for the treatment of patients with stage III, unresectable non–small cell lung cancer (NSCLC), based on positive progression-free survival ...Leggi tutto
FDA Grants Olaparib Priority Review in BRCA+ Breast Cancer
October 18, 2017 - The FDA has granted a priority review to a supplemental New Drug Application (sNDA) for olaparib for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, ...Leggi tutto
Web-app
Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore del pancreas è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, ...Leggi tutto